![](https://investorshub.advfn.com/uicon/617240.png?cb=1527076501)
Tuesday, March 17, 2020 4:29:11 PM
Recent COCP News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 12:00:14 PM
- Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences • GlobeNewswire Inc. • 08/19/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 12:00:40 PM
- Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs • GlobeNewswire Inc. • 08/14/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 01:00:13 PM
- Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor • GlobeNewswire Inc. • 07/18/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:30:41 PM
- New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows • GlobeNewswire Inc. • 06/20/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 12:15:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 12:00:46 PM
- Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs • GlobeNewswire Inc. • 05/13/2024 12:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/07/2024 08:30:24 PM
- Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza • GlobeNewswire Inc. • 05/01/2024 12:00:00 PM
- Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs • GlobeNewswire Inc. • 03/28/2024 12:00:00 PM
- Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A • GlobeNewswire Inc. • 03/19/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 09:15:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:00:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:01:43 PM
- Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/02/2024 02:53:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 10:00:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 01:00:40 PM
- Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A • GlobeNewswire Inc. • 12/06/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 01:00:25 PM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Mawson Finland Provides Update on Exploration Activities at Rajapalot • MFL • Aug 21, 2024 9:06 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM